770719-09-0

Basic information

• Product Name: 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile
• Synonyms: 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile
• CAS NO: 770719-09-0
• Molecular Weight: 310.644
• Mol File: 770719-09-0.mol

Chemical Properties

• CAS DataBase Reference: 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile(770719-09-0)
• EPA Substance Registry System: 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile(770719-09-0)

Safety Data

• Hazardous Substances Data: 770719-09-0(Hazardous Substances Data)

Upstream product

• 473923-96-5 3-chloro-5-methoxybenzonitrile 
• 6575-00-4 3,5-dichlorobenzonitrile 
• 473923-97-6 3-chloro-5-hydroxybenzonitrile 
• 771-69-7 2,3,4-trifluoronitrobenzene 

Downstream Products

• 867367-05-3 1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl} propanedioate 
• 1003605-03-5 C₁₃H₆ClFN₂O₄ 
• 1093988-29-4 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)phenyl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1093988-28-3 4-chloro-3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropylbenzenesulfonamide 
• 1093988-27-2 4-chloro-5-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-2-fluoro-N-methylbenzenesulfonamide 
• 1093988-26-1 5-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-2-methylbenzenesulfonamide 
• 1093988-25-0 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-(3-hydroxypropyl)benzamide 
• 1093988-24-9 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropylbenzamide 
• 1093988-23-8 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-[2-(4-morpholinyl)ethyl]benzamide 
• 1093988-22-7 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-[2-(methylsulfonyl)ethyl]benzamide 
• 1093988-20-5 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-(2,3-dihydroxypropyl)benzamide 
• 1093988-21-6 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]-N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]benzamide 
• 1093988-19-2 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]benzamide 
• 1093988-18-1 3-[5-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1,3,4-oxadiazol-2-yl]benzoic acid 

Relevant articles and documents

Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based o

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.